2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ratto, E. Articles by Pontremoli, R. Search for Related Content PubMed PubMed Citation Articles by Ratto, E. Articles by Pontremoli, R.

Metabolic Syndrome and Cardiovascular Risk in Primary Hypertension

Department of Internal Medicine, University of Genoa, and Department of Cardio-Nephrology, Azienda Opedaliera Universitaria San Martino, Genoa, Italy

Address correspondence to: Dr. Roberto Pontremoli, Department of Internal Medicine, University of Genoa, and Department of Cardio-Nephrology, Azienda Opedaliera Universitaria San Martino, Viale Benedetto XV 6, 16132 Genoa, Italy. Phone: +39-010-353-8932; Fax: +39-010-353-8932; E-mail: roberto.pontremoli{at}unige.it

The metabolic syndrome can be found in approximately one third of patients who do not have diabetes but have primary hypertension. Its presence has been associated with a wide range of traditional and nontraditional cardiovascular risk factors and early signs of cardiovascular and renal damage. Moreover, it was emphasized recently that the metabolic syndrome predicts an increased probability of sustaining a cardiovascular event or dying. In the clinical setting of insulin resistance, attention should be paid to the metabolic side effects of antihypertensive drugs; therefore, preference should be given to renin-angiotensin system inhibitors and calcium channel blockers rather than to blockers and diuretics.

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673